Diagnosis Of Active TB Using Aptamers | 9214
ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Diagnosis of active TB using aptamers

2nd International Conference and Exhibition on Pathology

Makobetsa Khati

ScientificTracks Abstracts: J Clin Exp Pathol

DOI: 10.4172/2161-0681.S1.008

Alack of simple, rapid, accurate, and affordable point-of-care diagnostic tools tailored to detect active TB early enough for opportune intervention in high HIV and TB prevalence developing countries is one of defining public health problems of our generation. Therefore, to help address this problem of unmet TB diagnostic needs in developing countries; we isolated sensitive and specific classes of novel artificial nucleic acid molecules called aptamers against the 10-kDa culture filtrate protein (CFP-10) and the 6-kDa early secreted antigen target (ESAT-6), which are potent T-cell antigens that are recognised by over 70% of TB patients. We then used these aptamers to develop a TB diagnostic tool that can be used at point-of-care for early and rapid detection of the disease. We have shown in a proof-of-concept case-controlled study that the aptamer-based diagnostic tool was able to accurately detect all cases of active TB from sputum samples of patients, including smear-negative culture positive and samples from patients co-infected with HIV.
Makobetsa Khati holds several degrees including a Masters in Molecular Medicine from the Imperial College School of Medicine at the Hammersmith Hospital in London; a Masters in Public Health from the School of Public Health and Family Medicine, University of Cape Town; and a Doctorate in Molecular Pathology from the Sir William Dunn School of Pathology, University of Oxford. He is currently Head of the Emerging Health Technologies Department at the CSIR. He is also an Honorary Associate in the Department of Medicine at Groote Schuur Hospital and the University of Cape Town